Personal information

Other IDs

Loop profile: 156919

Activities

Collapse all

Works (4)

Effective treatment of refractory monoclonal gammopathy‐associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone

eJHaem
2024-08 | Journal article
DOI: 10.1002/jha2.964
Contributors: Christian Sebastian Michel; Eva Marie Fehr; Hildegard Nolte; Joachim Beck; Andreas Kreft; Katharina Theresa Rauschkolb‐Olk; Bjoern Jacobi; Matthias Theobald; Markus Munder
Source: check_circle
Crossref

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Journal of Clinical Oncology
2024-01-01 | Journal article
DOI: 10.1200/JCO.23.01696
Contributors: Lisa B. Leypoldt; Diana Tichy; Britta Besemer; Mathias Hänel; Marc S. Raab; Christoph Mann; Markus Munder; Hans Christian Reinhardt; Axel Nogai; Martin Görner et al.
Source: check_circle
Crossref

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology
2023-03-10 | Journal article
DOI: 10.1200/JCO.21.02734
Contributors: Pieter Sonneveld; Asher Chanan-Khan; Katja Weisel; Ajay K. Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria-Victoria Mateos et al.
Source: check_circle
Crossref

Lethal systemic and brain infection caused by Prototheca zopfii algae in a patient with acute myeloid leukemia

Medical Mycology Case Reports
2021-06 | Journal article
DOI: 10.1016/j.mmcr.2021.01.004
Contributors: Stephanie Herold; Tristan Klodt; Daniela Toelle; Martin Dennebaum; Elena Lippe; Cleo Walz; Joachim Kaes; Andreas Kreft; Ekkehard Siegel; Markus Munder et al.
Source: check_circle
Crossref
How many people are using ORCID?